Xavier Becerra, who has led the Department of Health and Human Services, says federal agencies are outmatched in a world of ...

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

AG Ken Paxton pushed debunked misinformation about COVID-19 vaccines. What a shame the damage can’t be undone as easily as ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Clegg, former leader of the centrist Liberal Democrats in England, will be replaced by someone much closer to the Trump way ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

At the urging of the group Do No Harm, a 2-1 court panel revisted a decision it issued last year holding the organization ...

While Pfizer COVID vaccine is known to have multiple side effects, many women have been complaining of enlarged breasts.

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...